Better Context → Better Decisions
Context counts in life sciences. The FENIX analyst team is tirelessly using its experience to put you in a position to succeed. Below, our readers with corporate access will find a wealth of contextualized life science insight ready to be viewed in the FENIX Marketplace.
Welcome to FENIX Syndicated Services. If you already have an account, please log in. If you have any questions or would like to subscribe to our services, please contact us.
$599
Posted in: Bolus Insulin, SGLT2i Nov 01 | 2018Lexicon and MannKind Q3 '18 Earnings UpdatesPurchase Blast$599
Posted in: Basal Insulin, Bolus Insulin, Dual/triple agonist, GLP-1RA, GLP-1RA + Basal, Glucagon Nov 01 | 2018Novo to Pursue High-Dose Ozempic for T2DM; Q3 '18 Earnings UpdatePurchase Blast$599
Posted in: Glucose Monitoring Nov 01 | 2018Dexcom Verily G1 Approved, But Will It Launch?Purchase Blast$599
Posted in: Basal Insulin, Bolus Insulin, Dual/triple agonist, GLP-1RA, GLP-1RA + Basal Oct 31 | 2018Sanofi Q3 '18 Earnings UpdatePurchase Blast$599
Posted in: DPP-IVi, SGLT2i Oct 30 | 2018UPDATED: Invokana 3P-MACE Indication ApprovedPurchase Blast$599
Posted in: Basal Insulin, Bolus Insulin Oct 26 | 2018Biocon CY Q3 '18 (FY Q2 '19) Earnings UpdatePurchase Blast$599
Posted in: GLP-1RA, GLP-1RA + Basal Oct 26 | 2018Oral Semaglutide + Basal Insulin (PIONEER 8) Positive Topline ResultsPurchase Blast$599
Posted in: Basal Insulin, DPP-IVi, Dual/triple agonist, SGLT2i Oct 25 | 2018Merck Q3 ’18 Earnings Update; No BS-Glargine DiscussionPurchase Blast$599
Posted in: Basal Insulin, GLP-1RA Oct 23 | 2018New Sanofi Efpeglenatide + Glargine Study (AMPLITUDE-L)Purchase Blast$599
Posted in: Basal Insulin, Bolus Insulin, GLP-1RA, Insulin Delivery Oct 23 | 2018Novo Partners with Flex for Connected Care Data ManagementPurchase Blast$599
Posted in: Basal Insulin, Bolus Insulin Oct 23 | 2018Novo to Launch Connected Pens and New Connected Care Partnerships with Dexcom, Roche, and GlookoPurchase Blast$599
Posted in: Glucagon Oct 23 | 2018Xeris Glucagon Filing Accepted by FDA; June 10, 2019 PDUFAPurchase Blast
$599
Posted in: Glucose Monitoring, Topics Oct 18 | 2018Dexcom G6 Medicare Availability in Early 2019; New Data Partnership with ValidicPurchase Blast$599
Posted in: Glucose Monitoring Oct 18 | 2018Dexcom G6 Medicare Availability in Early 2019; New Data Partnership with ValidicPurchase Blast
$599
Posted in: GLP-1RA, Topics Oct 17 | 2018New Ozempic “Real-World Pragmatic Study” with AnthemPurchase Blast
$599
Posted in: Glucose Monitoring, Insulin Delivery, Topics Oct 17 | 2018Abbott and Roche Q3 '18 Earnings UpdatesPurchase Blast
$599
Posted in: Bolus Insulin, Topics Oct 16 | 2018MannKind Receives Warning for Afrezza Facebook PromoPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, DPP-IVi, Dual/triple agonist, GLP-1RA, GLP-1RA + Basal, Glucagon, Glucose Monitoring, Insulin Delivery, Other, SGLT2i, Topics Oct 16 | 2018J&J Q3 '18 Earnings UpdatePurchase Blast$599
Posted in: Basal Insulin, Bolus Insulin, DPP-IVi, Dual/triple agonist, GLP-1RA, GLP-1RA + Basal, Glucagon, Glucose Monitoring, Insulin Delivery, SGLT2i, Topics Oct 15 | 2018AZ’s Head of CVRM Joins NovoPurchase Blast